RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing FDA Decision: Intra-Cellular Therapies (ITCI)

The Phase 3 date for RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing by Intra-Cellular Therapies (ITCI) is scheduled for November 19, 2028. This is the target date for the FDA to make a decision on this application.

RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing is being developed by Intra-Cellular Therapies for the treatment of its target indication. It is currently in Phase 3 clinical trials.

If RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing receives FDA approval, Intra-Cellular Therapies (ITCI) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 3 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for ITCI on DilutionWatch at dilutionwatch.com/stock/ITCI.html.

You can view the full BiotechSign company profile for Intra-Cellular Therapies (ITCI) at biotechsign.com/app/company/ITCI, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.